According to a new report from Intel Market Research, the global Travel eSIM market was valued at USD 325.62 million in 2023 and is projected to reach USD 734.16 million by 2030, growing at a CAGR of 12.36% during the forecast period (2024-2030).

What is Travel eSIM?

Travel eSIM, or embedded SIM, is a revolutionary technology that eliminates the need for a physical SIM card, allowing users to switch between network providers seamlessly. This technology is particularly beneficial for frequent travelers, enabling them to access mobile networks in multiple countries without changing SIM cards. Travel eSIMs are widely used in business travel, leisure travel, and study abroad programs, offering cost-effective and hassle-free connectivity solutions.

Market Dynamics

Drivers

  • Increasing International Travel: The growing number of international travelers for business, tourism, and education is a significant driver for the Travel eSIM market.
  • Convenience & Cost-Effectiveness: eSIMs offer seamless connectivity, eliminating roaming charges and the hassle of purchasing local SIM cards.
  • Growing Adoption of IoT & Smart Devices: The rise of eSIM-compatible devices, such as smartphones, tablets, and smartwatches, is propelling demand.
  • Expansion of 5G Networks: The rapid rollout of 5G enhances the user experience by offering faster and more reliable internet connectivity.

Restraints

  • Limited Compatibility with Devices: Not all smartphones and devices support eSIM technology, which can slow down market adoption.
  • Lack of Awareness: Many consumers are still unaware of eSIM technology and its benefits.
  • Regulatory Challenges: Different regulations across countries regarding eSIM activation can hinder market expansion.

Opportunities

  • Integration with Smart Travel Solutions: Travel eSIMs can be integrated with digital travel platforms for an enhanced experience.
  • Emerging Markets Adoption: Regions like Africa and Latin America present untapped growth potential.
  • Partnerships with Telecom Providers: Collaborations between eSIM providers and mobile network operators can expand service offerings.

Challenges

  • Cybersecurity Risks: Ensuring secure authentication and data protection remains a challenge for eSIM technology.
  • Fragmented Market Competition: The presence of multiple players with varied pricing and service models leads to market fragmentation.

Regional Analysis

North America

  • Market Share: 27.7% (2023)
  • Major Players: Holafly, Airalo, Vodafone
  • Growth Drivers: High smartphone penetration, strong telecom infrastructure, and increased business travel demand.

Europe

  • Market Share: 25.6% (2023)
  • Major Players: Ubigi, Bouygues Telecom, Sim Local
  • Growth Drivers: EU-wide regulatory support for eSIM, high travel frequency within Schengen countries.

Asia-Pacific

  • Market Share: 19.9% (2023)
  • Major Players: Flexiroam, Sakura Mobile
  • Growth Drivers: Growing middle class, increasing international students, expanding digital economy.

Latin America & Middle East

  • Market Share: 16.8% (2023)
  • Major Players: Drimsim, TravelSim
  • Growth Drivers: Increasing tourism, mobile adoption, and digital transformation.

Competitor Analysis

Major Players & Market Share (2023)

  • Holafly
  • Airalo
  • Bouygues Telecom
  • Ubigi
  • Vodafone
  • Matrix Cellular
  • Airhub
  • Flexiroam
  • Sakura Mobile
  • Drimsim
  • Mayamobile

These companies collectively hold approximately 35% of the total market revenue.

Global Travel eSIM: Market Segmentation Analysis

This report provides a deep insight into the global Travel eSIM market, covering essential aspects such as market trends, competitive landscape, niche markets, key drivers, and SWOT analysis.

Market Segmentation (by Application)

  • Individual Travelers
  • Corporate Travelers
  • Group Travelers
  • Frequent Travelers

Market Segmentation (by Type)

  • 4G eSIM
  • 5G eSIM

By Type of eSIM:

  • Standalone eSIM
  • Combinational eSIM

By Data Plan:

  • Prepaid eSIMs
  • Postpaid eSIMs
  • Unlimited Data Plans
  • Pay-As-You-Go

By Duration:

  • Short-Term eSIMs
  • Long-Term eSIMs
  • One-Time Use eSIMs

By End-User Device:

  • Smartphones
  • Tablets
  • Laptops
  • Wearables
  • IoT Devices

By Technology:

  • 4G LTE eSIMs
  • 5G eSIMs

By Pricing:

  • Budget eSIMs
  • Mid-Range eSIMs
  • Premium eSIMs

Key Companies

  • Holafly
  • Airalo
  • Bouygues Telecom
  • Ubigi
  • Vodafone
  • Matrix Cellular
  • Airhub
  • Flexiroam
  • Sakura Mobile
  • Drimsim
  • Mayamobile

Geographic Segmentation

  • North America (U.S., Canada)
  • Asia-Pacific (China, Japan, South Korea, India, Australia)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Latin America (Mexico, Brazil, Argentina, Colombia)
  • Middle East & Africa

FAQ

What is the current market size of the Travel eSIM industry?

▶ As of 2023, the global Travel eSIM market was valued at US$ 325.62 million and is projected to reach US$ 734.16 million by 2030.

Which are the key companies operating in the Travel eSIM market?

▶ Major companies include Holafly, Airalo, Bouygues Telecom, Ubigi, Vodafone, Matrix Cellular, Airhub, Flexiroam, and Sakura Mobile.

What are the key growth drivers in the Travel eSIM market?

▶ Key drivers include increasing international travel, cost-effective connectivity, rapid 5G expansion, and growing IoT adoption.

Which regions dominate the Travel eSIM market?

▶ North America and Europe hold the largest market shares, followed by Asia-Pacific as an emerging leader.

What are the emerging trends in the Travel eSIM market?

▶ Trends include wider adoption of 5G, increased smartphone compatibility, integration with digital travel platforms, and regulatory support for eSIM activation.

According to a new report from Intel Market Research, the global Afamelanotide market was valued at USD 136.27 million in 2024 and is projected to reach USD 258.01 million by 2032, growing at a robust CAGR of 9.1% during the forecast period (2025–2032). This growth is propelled by the increasing global prevalence of rare phototoxic disorders, heightened awareness about orphan diseases, and advancements in melanocortin-based peptide therapies.

What is Afamelanotide?

Afamelanotide is a first-in-class synthetic analog of α-MSH (alpha-melanocyte-stimulating hormone), a naturally occurring hormone responsible for skin pigmentation and immune modulation. The drug is primarily indicated for Erythropoietic Protoporphyria (EPP)—a rare, inherited disorder characterized by severe phototoxic reactions to sunlight. Afamelanotide acts by stimulating melanin production, thereby enhancing photoprotection and significantly improving quality of life for patients.

Marketed under the brand name SCENESSE®, Afamelanotide is administered via subcutaneous implants and is currently approved for commercial use in the U.S., European Union, and Australia, making it the only approved treatment for EPP to date.

📥 Download Sample Report: https://www.intelmarketresearch.com/download-free-sample/912/Server-Automation-Market

Key Market Drivers

1. Rising Incidence of Rare Phototoxic and Pigmentary Disorders

The increasing identification and diagnosis of EPP—affecting an estimated 1 in 74,300 individuals worldwide—is a key factor fueling demand. A landmark clinical trial published in the New England Journal of Medicine (2015) demonstrated that Afamelanotide increased sunlight tolerance in EPP patients from 40 minutes to over 6 hours, significantly reducing pain and hospitalization rates.

2. Pipeline Expansion into Dermatological and Neurological Conditions

Afamelanotide is currently under investigation for a broader spectrum of disorders, including:

  • Vitiligo: When combined with narrowband UVB therapy, early studies showed repigmentation benefits.
  • Polymorphic Light Eruption (PMLE) and Solar Urticaria: Clinical trials are exploring Afamelanotide’s potential in reducing light-induced inflammatory responses.
  • Neurological disorders: Including exploratory trials in Parkinson’s disease and ACTH-related adrenal dysfunctions.

These developments position Afamelanotide as a platform therapy for both dermatological and systemic conditions influenced by melanocortin receptors.

Market Challenges

  • High treatment costs: Annual therapy costs range between USD 100,000 and 120,000 per patient, making reimbursement challenging, particularly in emerging markets.
  • Limited access in low-to-middle income countries: Availability is constrained due to the lack of reimbursement systems and regulatory delays.
  • Regulatory complexity: Securing approval for new indications demands extensive clinical trial data, requiring significant investment and long timelines.

Opportunities Ahead

The global shift toward rare disease recognition, patient advocacy, and orphan drug incentives presents a favorable outlook. Regions such as Asia-Pacific, Latin America, and Middle East & Africa are witnessing growing momentum through:

  • Revised orphan drug policies
  • Expanded clinical research infrastructure
  • Strategic partnerships with local distributors and academic institutions

Notably, CLINUVEL Pharmaceuticals, the innovator behind SCENESSE®, has announced its 2024–2025 expansion strategy, focusing on:

  • New clinical trials in vitiligo and Parkinson’s disease
  • Post-marketing surveillance in North America and Europe
  • Development of novel melanocortin analogs to diversify its product pipeline

📥 Download Sample PDF: https://www.intelmarketresearch.com/download-free-sample/912/Server-Automation-Market

Regional Market Insights

  • North America: Leads global market share owing to early FDA approval in 2019, strong insurance networks, and the presence of established patient registries.
  • Europe: A pioneer in EPP treatment access, granted EMA approval in 2014. The drug is now reimbursed in over 10 EU countries.
  • Asia-Pacific & Latin America: Emerging markets with large untapped patient pools, rising diagnostic capabilities, and potential for long-term growth.
  • Middle East & Africa: Currently underpenetrated but showing positive signs via NGO partnerships, international collaborations, and rising dermatology awareness.

Market Segmentation

By Application

  • Erythropoietic Protoporphyria (EPP)
  • Vitiligo
  • Photodermatoses
  • Melasma
  • Skin Cancer Prevention
  • Others

By End User

  • Hospitals
  • Specialty Clin